BA attenuated the decrease in the expression of ZO-1 and Occludin induced by LPS in Caco2 cells. حسب Luqiong Liu (11537092)

Simulated regional mean wetland seasons. حسب Nic Gedney (19762301)

الموضوعات:

Contemporary mean inundation fraction in the Amazon basin. حسب Nic Gedney (19762301)

الموضوعات:

Y-27632 collaborated with BA to attenuate the increase in the integrity and decrease in the permeability of epithelial barrier injury induced by LPS in Caco2 monolayers. حسب Luqiong Liu (11537092)

"…<p>(<b>A)</b> Y-27632 collaborated with BA to attenuate the effect of LPS on TEER in Caco2 cells on days 1–22. …"

Y-27632 synergized with BA to alleviate the decrease in the expression of and abnormal localization of ZO-1 and Occludin in LPS-induced Caco2 cells. حسب Luqiong Liu (11537092)

HSP90 inhibition by RGRN-305 and 17-AAG decreased proinflammatory protein secretion. حسب Hakim Ben Abdallah (14578241)

Regional contemporary (1990–1999 mean) precipitation and JULES inundation fraction over the Amazon basin. حسب Nic Gedney (19762301)

الموضوعات:

ANN architecture. حسب Abdelfattah Dani (22226715)

ANN architecture and configuration. حسب Abdelfattah Dani (22226715)

HSP90 inhibition by RGRN-305 decreased the gene expression of proinflammatory cytokines induced by SARS-CoV-2 S protein. حسب Hakim Ben Abdallah (14578241)

Descriptive statistics (means) for full sample and by lockdown status. حسب Drew B. Cameron (10687420)

Random forest plot showing the importance of predictors (top 10) for classifying LF progression based on the Mean Decrease in Gini index. حسب Emmanuel Kobla Atsu Amewu (13946765)

Distribution of final population size (A) and mean change in mean MSI over time (B) over 100 simulations for each parameter set shown in Table 3 in the absence of weevils (left) an... حسب Alexandra M. Campbell (3284094)

الموضوعات:

Illustration of BSC control using ANN for WECS. حسب Abdelfattah Dani (22226715)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. حسب Elizabeth S. Munroe (21568166)

Antibody and antigen responses to Ensovibep vs placebo day 1–90. حسب Elizabeth S. Munroe (21568166)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. حسب Elizabeth S. Munroe (21568166)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. حسب Elizabeth S. Munroe (21568166)

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. حسب Elizabeth S. Munroe (21568166)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. حسب Elizabeth S. Munroe (21568166)